Dose-escalation, PK- and Safety Study With Single Agent CetuGEX in Patients With EGFR Positive Locally Advanced and/or Metastatic Cancer.

Trial Profile

Dose-escalation, PK- and Safety Study With Single Agent CetuGEX in Patients With EGFR Positive Locally Advanced and/or Metastatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Apr 2014 Tolerability and efficacy data presented, according to a Glycotope media release.
    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jul 2013 Promising first-in-man data were presented at ASCO 2013, according to a Glycotope media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top